Journal of Molecular Endocrinology

References

1. ↵
   1. Andersen M,
   2. Bjerre P,
   3. Schrøder HD,
   4. Edal A,
   5. Høilund-Carlsen PF,
   6. Pedersen PH &
   7. Hagen C

   2001 In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non-functioning pituitary adenomas. Clinical Endocrinology 54 23–30.
2. ↵
   1. Asa S,
   2. Kovacs K,
   3. Horvath E,
   4. Singer W &
   5. Smyth HS

   1992 Hormone secretion in vitro by plurihormonal pituitary adenomas of the acidophilic cell line. Journal of Clinical Endocrinology and Metabolism 75 68–75.
3. ↵
   1. Batista DL,
   2. Zhang X,
   3. Gejman R,
   4. Ansell PJ,
   5. Zhou Y,
   6. Johnson SA,
   7. Swearingen B,
   8. Hedley-Whyte ET,
   9. Stratakis CA &
   10. Klibanski A

   2006 The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 91 4482–4488.
4. ↵
   1. Beck-Peccoz P &
   2. Persani L

   2002 Medical management of thyrotropin-secreting pituitary adenomas. Pituitary 5 83–88.
5. ↵
   1. Ben-Jonathan N &
   2. Hnasko R

   2001 Dopamine as a prolactin (PRL) inhibitor. Endocrine Reviews 22 724–7638.
6. ↵
   1. Ben-Shlomo A &
   2. Melmed S

   2007 Pasireotide: a somatostatin analog for the potential treatment of acromegaly, neuroendocrine tumors and Cushing's disease. Drugs 10 885–895.
7. ↵
   1. Bevan JS

   2005 Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly. Journal of Clinical Endocrinology and Metabolism 90 1856–1863.
8. ↵
   1. de Bruin C,
   2. Feelders RA,
   3. Lamberts SWJ &
   4. Hofland LJ

   2009 Somatostatin and dopamine receptors as targets for medical treatment of Cushing's Syndrome. Reviews in Endocrine and Metabolic Disorders 42 47–56.
9. ↵
   1. de Bruin C,
   2. Feelders R,
   3. Waaijers M,
   4. van Koetsveld P,
   5. Sprij-Mooij D,
   6. Lamberts S &
   7. Hofland L

   2008a Differential regulation of human dopamine D2 and somatostatin receptor subtype expression by glucocorticoids in vitro. Journal of Molecular Endocrinology 149 4357–4366.
10. ↵
    1. de Bruin C,
    2. Hanson JM,
    3. Meij BP,
    4. Kooistra HS,
    5. Waaijers AM,
    6. Uitterlinden P,
    7. Lamberts SWJ &
    8. Hofland LJ

    2008b Expression and functional analysis of dopamine D2 and somatostatin receptor subtypes in canine Cushing's disease. Endocrinology 149 4357–4366.
11. ↵
    1. Burt MG &
    2. Ho KKY

    2006 Newer options in the management of acromegaly. Internal Medicine Journal 36 437–444.
12. ↵
    1. Casarini AP,
    2. Pinto EM,
    3. Jallad RS,
    4. Giorgi RR,
    5. Giannella-Neto D &
    6. Bronstein MD

    2006 Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3. Journal of Endocrinological Investigation 29 826–830.
13. ↵
    1. Colao A,
    2. Filippella M,
    3. Pivonello R,
    4. Di Somma C,
    5. Faggiano A &
    6. Lombardi G

    2007 Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours. European Journal of Endocrinology 156 S57–S63.
14. ↵
    1. Colao A,
    2. Di Somma C,
    3. Pivonello R,
    4. Faggiano A,
    5. Lombardi G &
    6. Savastano S

    2008 Medical therapy for clinically non-functioning pituitary adenomas. Endocrine-Related Cancer 15 905–915.
15. ↵
    1. Cozzi R,
    2. Attanasio R,
    3. Lodrini S &
    4. Lasio G

    2004 Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clinical Endocrinology 61 209–215.
16. ↵
    1. Cozzi R,
    2. Montini M,
    3. Attanasio R,
    4. Albizzi M,
    5. Lasio G,
    6. Lodrini S,
    7. Doneda P,
    8. Cortesi L &
    9. Pagani G

    2006 Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. Journal of Clinical Endocrinology and Metabolism 91 1397–1403.
17. ↵
    1. Cremonini N,
    2. Graziano E,
    3. Chiarini V,
    4. Sforza A &
    5. Zampa GA

    1992 Atypical McCune-Albright syndrome associated with growth hormone-prolactin pituitary adenoma: natural history, long-term follow-up, and SMS 201–995 – bromocriptine combined treatment results. Journal of Clinical Endocrinology and Metabolism 75 1166–1169.
18. ↵
    1. Durán-Prado M,
    2. Malagón MM,
    3. Gracia-Navarro F &
    4. Castaño JP

    2008 Dimerization of G protein-coupled receptors: new avenues for somatostatin receptor signalling, control and functioning. Molecular and Cellular Endocrinology 286 63–68.
19. ↵
    1. Ferone D,
    2. Pivonello R,
    3. Lastoria S,
    4. Faggiano A,
    5. Del Basso de Caro ML,
    6. Cappabianca P,
    7. Lombardi G &
    8. Colao A

    2001 In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy. Clinical Endocrinology 54 469–477.
20. ↵
    1. Ferone D,
    2. Arvigo M,
    3. Semino C,
    4. Jaquet P,
    5. Saveanu A,
    6. Taylor JE,
    7. Moreau JP,
    8. Culler MD,
    9. Albertelli M,
    10. Minuto F
    11. et al.

    2005 Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation. American Journal of Physiology. Endocrinology and Metabolism 289 E1044–E1050.
21. ↵
    1. Ferone D,
    2. Pivonello R,
    3. Resmini E,
    4. Boschetti M,
    5. Rebora A,
    6. Albertelli M,
    7. Albanese V,
    8. Colao A,
    9. Culler MD &
    10. Minuto F

    2007a Preclinical and clinical experiences with the role of dopamine receptors in the treatment of pituitary adenomas. European Journal of Endocrinology 156 S37–S43.
22. ↵
    1. Ferone D,
    2. Saveanu A,
    3. Culler MD,
    4. Arvigo M,
    5. Rebora A,
    6. Gatto F,
    7. Minuto F &
    8. Jaquet P

    2007b Novel chimeric somatostatin analogs: facts and perspectives. European Journal of Endocrinology 156 S23–S28.
23. ↵
    1. Ferone D,
    2. de Herder WW,
    3. Pivonello R,
    4. Kros JM,
    5. van Koetsveld PM,
    6. de Jong T,
    7. Minuto F,
    8. Colao A,
    9. Lamberts SWJ &
    10. Hofland LJ

    2008 Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. Journal of Clinical Endocrinology and Metabolism 93 1412–1417.
24. ↵
    1. Fløgstad AK,
    2. Halse J,
    3. Grass P,
    4. Abisch E,
    5. Djøseland O,
    6. Kutz K,
    7. Bodd E &
    8. Jervell J

    1994 A comparison of octreotide, bromocriptine, or a combination of both drugs in acromegaly. Journal of Clinical Endocrinology and Metabolism 79 461–465.
25. ↵
    1. Florio T

    2008 Somatostatin/somatostatin receptor signalling: phosphotyrosine phosphatases. Molecular and Cellular Endocrinology 286 40–48.
26. ↵
    1. Florio T,
    2. Barbieri F,
    3. Spaziante R,
    4. Zona G,
    5. Hofland LJ,
    6. van Koetsveld PM,
    7. Feelders RA,
    8. Stalla GK,
    9. Theodoropoulou M,
    10. Culler MD
    11. et al.

    2008 Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study. Endocrine-Related Cancer 15 583–596.
27. ↵
    1. Freda PU

    2002 Somatostatin analogs in acromegaly. Journal of Clinical Endocrinology and Metabolism 87 3013–3018.
28. ↵
    1. Fredstorp L,
    2. Kutz K &
    3. Werner S

    1994 Treatment with octreotide and bromocriptine in patients with acromegaly: an open pharmacodynamic interaction study. Clinical Endocrinology 41 103–108.
29. ↵
    1. Fusco A,
    2. Gunz G,
    3. Jaquet P,
    4. Dufour H,
    5. Germanetti AL,
    6. Culler MD,
    7. Barlier A &
    8. Saveanu A

    2007 Somatostatinergic ligands in dopamine-sensitive or -resistant prolactinomas. European Journal of Endocrinology 158 595–603.
30. ↵
    1. Gillam MP,
    2. Molitch ME,
    3. Lombardi G &
    4. Colao A

    2006 Advances in the treatment of prolactinomas. Endocrine Reviews 27 485–534.
31. ↵
    1. Grant M,
    2. Alturaihi H,
    3. Jaquet P,
    4. Collier B &
    5. Kumar U

    2008 Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization. Molecular Endocrinology 22 2278–2292.
32. ↵
    1. Greenman Y

    2007 Dopaminergic treatment of nonfunctioning pituitary adenomas. Nature Clinical Practice. Endocrinology & Metabolism 3 554–555.
33. ↵
    1. Gruszka A,
    2. Kunert-Radek J,
    3. Radek A,
    4. Pisarek H,
    5. Taylor J,
    6. Dong JZ,
    7. Culler MD &
    8. Pawlikowski M

    2006 The effect of selective sst1, sst2, sst5 somatostatin receptors agonists, a somatostatin/dopamine (SST/DA) chimera and bromocriptine on the ‘clinically non-functioning’ pituitary adenomas in vitro. Life Science 78 689–693.
34. ↵
    1. Guillemin R

    2005 Hypothalamic hormones a.k.a. hypothalamic releasing factors. Journal of Endocrinology 184 11–28.
35. ↵
    1. Hofland LJ &
    2. Lamberts SW

    2001 Somatostatin receptor subtype expression in human tumors. Annals of Oncology 12 S31–S36.
36. ↵
    1. Hofland LJ &
    2. Lamberts SWJ

    2003 The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocrine Reviews 24 28–47.
37. ↵
    1. Kidd M,
    2. Modlin IM,
    3. Black JW,
    4. Boyce M &
    5. Culler M

    2007 A comparison of the effects of gastrin, somatostatin and dopamine receptor ligands on rat gastric enterochromaffin-like cell secretion and proliferation. Regulatory Peptides 143 109–117.
38. ↵
    1. Kidd M,
    2. Drozdov I,
    3. Joseph R,
    4. Pfragner R,
    5. Culler M &
    6. Modlin I

    2008 Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines. Cancer 113 690–700.
39. ↵
    1. Lahlou H,
    2. Guillermet J,
    3. Hortala M,
    4. Vernejoul F,
    5. Pyronnet S,
    6. Bousquet C &
    7. Susini C

    2004 Molecular signaling of somatostatin receptors. Annals of the New York Academy of Sciences 1014 121–131.
40. ↵
    1. Lamberts SW,
    2. Zweens M,
    3. Verschoor L &
    4. del Pozo E

    1986 A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201–995, bromocriptine, and the combination of both drugs. Journal of Clinical Endocrinology and Metabolism 63 16–19.
41. ↵
    1. Lesche S,
    2. Lehmann D,
    3. Nagel F,
    4. Schmid HA &
    5. Schulz S

    2009 Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro. Journal of Clinical Endocrinology and Metabolism 94 654–661.
42. ↵
    1. Li JK,
    2. Chow CC,
    3. Yeung VT,
    4. Mak TW,
    5. Ko GT,
    6. Swaminathan R,
    7. Chan JC &
    8. Cockram CS

    2000 Treatment of Chinese acromegaly with a combination of bromocriptine and octreotide. Australian and New Zealand Journal of Medicine 30 457–461.
43. ↵
    1. Marzullo P,
    2. Ferone D,
    3. Di Somma C,
    4. Pivonello R,
    5. Filippella M,
    6. Lombardi G &
    7. Colao A

    1999 Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients. Pituitary 1 115–120.
44. ↵
    1. Miller GM,
    2. Alexander JM,
    3. Bikkal HA,
    4. Katznelson L,
    5. Zervas NT &
    6. Klibanski A

    1995 Somatostatin receptor subtype gene expression in pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 80 1386–1392.
45. ↵
    1. Minniti G,
    2. Jaffrain-Rea ML,
    3. Baldelli R,
    4. Ferretti E,
    5. Caracciolo B,
    6. Bultrini A,
    7. Gulino A &
    8. Tamburrano G

    1997 Acute effects of octreotide, cabergoline and a combination of both drugs on GH secretion in acromegalic patients. Clinica Terapeutica 148 601–607.
46. ↵
    1. Missale C,
    2. Nash SR,
    3. Robinson SW,
    4. Jaber M &
    5. Caron MG

    1998 Dopamine receptors: from structure to function. Physiological Reviews 78 189–225.
47. ↵
    1. Moller LN,
    2. Stidsen CE,
    3. Hartmann B &
    4. Holst JJ

    2003 Somatostatin receptors. Biochimica et Biophysica Acta 1616 1–84.
48. ↵
    1. Ness-Abramof R,
    2. Ishay A,
    3. Harel G,
    4. Sylvetzky N,
    5. Baron E,
    6. Greenman Y &
    7. Shimon I

    2007 TSH-secreting pituitary adenomas: follow-up of 11 cases and review of the literature. Pituitary 10 307–310.
49. ↵
    1. Ono K,
    2. Suzuki T,
    3. Miki Y,
    4. Taniyama Y,
    5. Nakamura Y,
    6. Noda Y,
    7. Watanabe M &
    8. Sasano H

    2007 Somatostatin receptor subtypes in human non-functioning neuroendocrine tumors and effects of somatostatin analogue SOM230 on cell proliferation in cell line NCI-H727. Anticancer Research 27 2231–2239.
50. ↵
    1. Panetta R &
    2. Patel YC

    1995 Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors. Life Sciences 56 333–342.
51. ↵
    1. Pasquali D,
    2. Rossi V,
    3. Conzo G,
    4. Pannone G,
    5. Bufo P,
    6. De Bellis A,
    7. Renzullo A,
    8. Bellastella G,
    9. Colao A,
    10. Vallone G
    11. et al.

    2008 Effects of somatostatin analog SOM230 on cell proliferation, apoptosis, and catecholamine levels in cultured pheochromocytoma cells. Journal of Molecular Endocrinology 40 263–271.
52. ↵
    1. Pivonello R,
    2. Ferone D,
    3. de Herder WW,
    4. Kros JM,
    5. De Caro ML,
    6. Arvigo M,
    7. Annunziato L,
    8. Lombardi G,
    9. Colao A,
    10. Hofland LJ
    11. et al.

    2004a Dopamine receptor expression and function in corticotroph pituitary tumors. Journal of Clinical Endocrinology and Metabolism 89 2452–2462.
53. ↵
    1. Pivonello R,
    2. Matrone C,
    3. Filippella M,
    4. Cavallo LM,
    5. Di Somma C,
    6. Cappabianca P,
    7. Colao A,
    8. Annunziato L &
    9. Lombardi G

    2004b Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment. Journal of Clinical Endocrinology and Metabolism 89 1674–1683.
54. ↵
    1. Pivonello R,
    2. Ferone D,
    3. Lamberts SW &
    4. Colao A

    2005 Cabergoline plus lanreotide for ectopic Cushing's syndrome. New England Journal of Medicine 352 2457–2458.
55. ↵
    1. Popović V,
    2. Nesović M,
    3. Mićić D,
    4. Kendereski A,
    5. Djordjević P,
    6. Manojlović D &
    7. Mićić J

    1990 A comparison among the effectiveness of growth hormone suppression in active acromegaly of bromocriptine and long acting somatostatin analogue (SMS 201–995). Experimental and Clinical Endocrinology 95 251–257.
56. ↵
    1. Renner U,
    2. Arzberger T,
    3. Pagotto U,
    4. Leimgruber S,
    5. Uhl E,
    6. Muller A,
    7. Lange M,
    8. Weindl A &
    9. Stalla GK

    1998 Heterogeneous dopamine D2 receptor subtype messenger ribonucleic acid expression in clinically nonfunctioning pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 83 1368–1375.
57. ↵
    1. Resmini E,
    2. Dadati P,
    3. Ravetti JL,
    4. Zona G,
    5. Spaziante R,
    6. Saveanu A,
    7. Jaquet P,
    8. Culler MD,
    9. Bianchi F,
    10. Rebora A
    11. et al.

    2007 Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient. Journal of Clinical Endocrinology and Metabolism 92 1592–1599.
58. ↵
    1. Rocheville M,
    2. Lange DC,
    3. Kumar U,
    4. Patel SC,
    5. Patel RC &
    6. Patel YC

    2000 Receptors for dopamine and somatostatin: formation of heterooligomers with enhanced functional activity. Science 288 154–157.
59. ↵
    1. Sadoul JL,
    2. Thyss A &
    3. Freychet P

    1992 Invasive mixed growth hormone/prolactin secreting pituitary tumour: complete shrinking by octreotide and bromocriptine, and lack of tumour growth relapse 20 months after octreotide withdrawal. Acta Endocrinologica 126 179–183.
60. ↵
    1. Saveanu A &
    2. Jaquet P

    2008 Somatostatin-dopamine ligands in the treatment of pituitary adenomas. Reviews in Endocrine and Metabolic Disorders(Epub ahead of print)
61. ↵
    1. Saveanu A,
    2. Jaquet P,
    3. Brue T &
    4. Barlier A

    2008 Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas. Molecular and Cellular Endocrinology 286 206–213.
62. ↵
    1. Saveanu A,
    2. Gunz G,
    3. Dufour H,
    4. Caron P,
    5. Fina F,
    6. Ouafik L,
    7. Culler MD,
    8. Moreau JP,
    9. Enjalbert A &
    10. Jaquet P

    2001 BIM-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. Journal of Clinical Endocrinology and Metabolism 86 140–145.
63. ↵
    1. Saveanu A,
    2. Gunz G,
    3. Guillen S,
    4. Dufour H,
    5. Culler MD &
    6. Jaquet P

    2006 Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas. Neuroendocrinology 83 258–263.
64. ↵
    1. Schonbrunn A

    2008 Selective agonism in somatostatin receptor signaling and regulation. Molecular and Cellular Endocrinology 286 35–39.
65. ↵
    1. Selvarajah D,
    2. Webster J,
    3. Ross R &
    4. Newell-Price J

    2005 Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. European Journal of Endocrinology 152 569–574.
66. ↵
    1. Stefaneanu L,
    2. Kovacs K,
    3. Horvath E,
    4. Buchfelder M,
    5. Fahlbusch R &
    6. Lancranjan L

    2001 Dopamine D2 receptor gene expression in human adenohypophysial adenomas. Endocrine 14 329–336.
67. ↵
    1. Taboada GF,
    2. Luque RM,
    3. Bastos W,
    4. Guimaraes RF,
    5. Marcondes JB,
    6. Chimelli LM,
    7. Fontes R,
    8. Mata PJ,
    9. Filho PN,
    10. Carvalho DP
    11. et al.

    2007 Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. European Journal of Endocrinology 156 65–74.
68. ↵
    1. Theodoropoulou M,
    2. Zhang J,
    3. Laupheimer S,
    4. Paez-Pereda M,
    5. Erneux C,
    6. Florio T,
    7. Pagotto U &
    8. Stalla GK

    2006 Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Research 66 1576–1582.
69. ↵
    1. Trouillas J,
    2. Chevallier P,
    3. Remy C,
    4. Rajas F,
    5. Cohen R,
    6. Calle A,
    7. Hooghe-Peters EL &
    8. Rousset B

    1999 Differential action of the dopamine agonist bromocriptine on growth of SMtTW tumor exhibiting a prolactin and/or somatotroph cell phenotype: relation to dopamine D2 receptor expression. Endocrinology 140 13–21.
70. ↵
    1. Tulipano G &
    2. Schulz S

    2007 Novel insights in somatostatin receptor physiology. European Journal of Endocrinology 156 S3–S11.
71. ↵
    1. Wagenaar AH,
    2. Harris AG,
    3. van der Lely AJ &
    4. Lamberts SW

    1991 Dynamics of the acute effects of octreotide, bromocriptine and both drugs in combination on growth hormone secretion in acromegaly. Acta Endocrinologica 125 637–642.
72. ↵
    1. Yoshihara A,
    2. Isozaki O,
    3. Hizuka N,
    4. Nozoe Y,
    5. Harada C,
    6. Ono M,
    7. Kawamata T,
    8. Kubo O,
    9. Hori T &
    10. Takano K

    2007 Expression of type 5 somatostatin receptor in TSH-secreting pituitary adenomas: a possible marker for predicting long-term response to octreotide therapy. Endocrine Journal 54 133–138.
73. ↵
    1. Zatelli MC,
    2. Piccin D,
    3. Tagliati F,
    4. Ambrosio MR,
    5. Margutti A,
    6. Padovani R,
    7. Scanarini M,
    8. Culler MD &
    9. degli Uberti EC

    2003 Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: effects on cell viability, GH, and PRL secretion. Journal of Clinical Endocrinology and Metabolism 88 2797–2802.
74. ↵
    1. Zatelli MC,
    2. Piccin D,
    3. Bottoni A,
    4. Ambrosio MR,
    5. Margutti A,
    6. Padovani R,
    7. Scanarini M,
    8. Taylor JE,
    9. Culler MD,
    10. Cavazzini L
    11. et al.

    2004 Evidence for differential effects of selective somatostatin receptor subtype agonists on alpha-subunit and chromogranin a secretion and on cell viability in human nonfunctioning pituitary adenomas in vitro. Journal of Clinical Endocrinology and Metabolism 89 5181–5188.
75. ↵
    1. Zatelli MC,
    2. Piccin D,
    3. Tagliati F,
    4. Bottoni A,
    5. Ambrosio MR,
    6. Margutti A,
    7. Scanarini M,
    8. Bondanelli M,
    9. Culler MD &
    10. degli Uberti EC

    2005 Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro. Journal of Molecular Endocrinology 35 333–341.